You are here

breast cancer

Seagen scores $41.8M in Enhertu patent case against Daiichi Sankyo

Fierce Pharma

Mon, 04/11/22 - 11:00 am

BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial

BioSpace

Thu, 04/7/22 - 10:39 am

Long wait for pivotal data on Sanofi's oral SERD ends in failure

Fierce Biotech

Mon, 03/14/22 - 10:32 am

clinical trials

That key Gilead breast cancer readout? Try 2024, and don't get your hopes up: analyst

Fierce Pharma

Wed, 03/9/22 - 10:51 am

Gilead Sciences

Gilead says breast cancer drug succeeded in key study, but offers few details

BioPharma Dive

Mon, 03/7/22 - 10:52 pm

Gilead Sciences

clinical trials

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

Pharmaforum

Mon, 02/21/22 - 10:35 am

clinical trials

HER2-low breast cancer

Radius falters after a PhIII osteoporosis fail and a breast cancer disappointment, sending shares plummeting

Endpoints

Thu, 12/9/21 - 10:56 am

clinical trials

Sanofi hit by filing delays for key drugs, drops an early Sangamo thalassemia asset

Fierce Biotech

Thu, 10/28/21 - 10:40 am

Trial For World’s First Potential Breast Cancer Vaccine Begins

BioSpace

Wed, 10/27/21 - 12:21 pm

clinical trials

Anixa Biosciences

Cleveland Clinic

Seagen’s breast cancer drug Tukysa turned down by NICE

Pharmaforum

Tue, 10/26/21 - 10:36 am

Menarini, chased by 3 Big Pharmas, records win in breast cancer phase 3, plots path to FDA

Fierce Biotech

Thu, 10/21/21 - 10:35 am

clinical trials

Keytruda maker Merck rolls web series to illuminate triple-negative breast cancer and Black women

Fierce Pharma

Wed, 10/20/21 - 06:49 pm

pharma marketing

triple negative breast cancer

Is AstraZeneca Set to Soar With an Advanced Breast Cancer Treatment?

Motley Fool

Thu, 10/14/21 - 11:00 am

clinical trials

Eli Lilly's Verzenio snags first-in-class FDA approval for early breast cancer. But limited label poses a challenge

Fierce Pharma

Wed, 10/13/21 - 11:07 am

early breast cancer

Enhertu nabs speedy FDA review for earlier use in breast cancer

Pharmaforum

Mon, 10/4/21 - 10:57 am

ESMO: Syros targets KRAS-mutant cancer as CDK7 inhibitor shows early promise

Fierce Biotech

Mon, 09/20/21 - 12:00 pm

Syros Pharmaceuticals

Novartis presents new Kisqali data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

Drugs.com

Sun, 09/19/21 - 11:58 pm

clinical trials

AstraZeneca, Daiichi Sankyo's ADC Enhertu blows away Roche's Kadcyla in second-line advanced breast cancer

Endpoints

Sat, 09/18/21 - 08:34 pm

ESMO21: Roche’s giredestrant takes stage in battle of the oral SERDs

Pharmaforum

Fri, 09/17/21 - 11:36 am

ESMO 2021 – the jury remains out on CDK7 inhibition

EP Vantage

Fri, 09/17/21 - 11:02 am

Syros Pharmaceuticals

Carrick Therapeutics

Pages